FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type ...
The FDA cleared an automated insulin delivery system for use by pregnant women with type 1 diabetes, according to an industry ...
Tandem Diabetes Care (Nasdaq:TNDM) today announced FDA clearance for its automated insulin delivery technology for use in ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
Tandem Diabetes Care, Inc. TNDM recently commercially launched Control-IQ+ technology - the latest generation of its advanced hybrid closed-loop algorithm in the United States. Control-IQ+ is ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine ...
Tandem Diabetes Care Inc.’s Control-IQ+ automated insulin delivery system improved multiple measures of glycemic control in individuals with type 2 diabetes who use insulin, a study presented March 19 ...
– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results